| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/27/2011 | WO2011133948A2 Highly active polypeptides and methods of making and using the same |
| 10/27/2011 | WO2011133879A2 Combination therapies with mitochondrial-targeted anti-tumor agents |
| 10/27/2011 | WO2011133735A2 Uses of natriuretic peptide constructs |
| 10/27/2011 | WO2011133687A2 Methods and compositions for inhibition of beta2-adrenergic receptor degradation |
| 10/27/2011 | WO2011133685A2 Nanoparticle targeting to ischemia for imaging and therapy |
| 10/27/2011 | WO2011133566A2 Repairing bruch's membrane with hydrogels |
| 10/27/2011 | WO2011133559A2 Alpha tubulin acetyltransferase |
| 10/27/2011 | WO2011133555A2 Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration |
| 10/27/2011 | WO2011133512A1 Rtef-1 variants and uses thereof |
| 10/27/2011 | WO2011133504A2 Nanozymes, methods of making nanozymes, and methods of using nanozymes |
| 10/27/2011 | WO2011133434A1 Methods of treating glucose metabolism disorders |
| 10/27/2011 | WO2011133429A1 Cancer-related glycopeptide epitopes, antibodies and methods of use |
| 10/27/2011 | WO2011133224A1 Organic compounds |
| 10/27/2011 | WO2011133204A1 Methods and assays for treating or preventing obesity and/or diabetes or increasing insulin sensitivity |
| 10/27/2011 | WO2011133112A1 Cell penetrating peptide derived from the premembrane protein of flavivirus |
| 10/27/2011 | WO2011132955A2 Use of hades as tumor suppressor target |
| 10/27/2011 | WO2011132943A2 Composition for treatment of acute pseudomembranous colitis |
| 10/27/2011 | WO2011132713A1 Lipid membrane structure with nuclear transferability |
| 10/27/2011 | WO2011132201A1 A pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent |
| 10/27/2011 | WO2011132191A1 Casein peptide for use in the treatment of uterine infections |
| 10/27/2011 | WO2011132189A2 High affinity leptins and leptin antagonists |
| 10/27/2011 | WO2011131896A2 Peptide derivatives, preparation thereof and uses thereof as vectors |
| 10/27/2011 | WO2011131658A1 Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof |
| 10/27/2011 | WO2011131646A1 Long-acting gastrin derivatives |
| 10/27/2011 | WO2011131626A1 Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity |
| 10/27/2011 | WO2011131360A2 Method of determining the metastatic potential of a tumor |
| 10/27/2011 | WO2011130824A1 Hb-egf composition and use thereof to treat a condition associated with enhanced urothelium permeability |
| 10/27/2011 | WO2011130800A1 Eczema treatment |
| 10/27/2011 | WO2011130799A1 Pharmaceutical compositions |
| 10/27/2011 | WO2011130798A1 Cold treatment |
| 10/27/2011 | WO2011106703A3 Cxcr4 receptor compounds |
| 10/27/2011 | WO2011103567A3 Peptides and methods for inducing cell death |
| 10/27/2011 | WO2011101881A3 Use of rho gtpase activating toxins for the treatment and/or prevention symptomatology associated with rett syndrome |
| 10/27/2011 | WO2011084451A3 Methods and compositions for liquidation of tumors |
| 10/27/2011 | WO2011081915A3 Methods for treating erectile dysfunction in patients with insulin-dependent diabetes |
| 10/27/2011 | WO2011069227A8 Anti-microbial agent from paenibacillus sp. and methods and uses thereof |
| 10/27/2011 | WO2011068853A3 TREATMENT OF IgE-MEDIATED DISEASE |
| 10/27/2011 | WO2011066182A3 Socs3 inhibition promotes cns neuron regeneration |
| 10/27/2011 | WO2011059779A3 Ligand-targeted multi- stereoisomer peptide polymer conjugates and uses thereof |
| 10/27/2011 | WO2011059262A3 Uses of apoptotic cell-targeting peptides, label substances and liposomes containing a therapeutic agent for preventing, treating or therapeutically diagnosing apoptosis-related diseases |
| 10/27/2011 | WO2011057160A3 Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 |
| 10/27/2011 | WO2011046622A3 Mutant low-density lipoprotein receptor related protein with increased binding to alzheimer amyloid-beta peptide |
| 10/27/2011 | WO2011038149A3 Methods of treating inflammation |
| 10/27/2011 | WO2010133367A3 Novel solid materials of {[2s, 5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them |
| 10/27/2011 | WO2009140269A3 Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis |
| 10/27/2011 | US20110265198 Genome editing of a Rosa locus using nucleases |
| 10/27/2011 | US20110265195 Unique associated kaposi's sarcoma virus sequences and uses thereof |
| 10/27/2011 | US20110264077 Solvent/polymer solutions as suspension vehicles |
| 10/27/2011 | US20110263831 NUCLEAR FACTOR kappaB INDUCING FACTOR |
| 10/27/2011 | US20110263817 Metal-binding compounds and uses therefor |
| 10/27/2011 | US20110263690 Methods and Compositions for use in Gene Therapy for Treatment of Hemophilia |
| 10/27/2011 | US20110263683 RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
| 10/27/2011 | US20110263678 Inhibitors of tgf-r signaling for treatment of cns disorders |
| 10/27/2011 | US20110263522 Antitumour compositions containing taxane derivatives |
| 10/27/2011 | US20110263517 Cytokines and Cytokine Receptors with Reduced Immunogenicity |
| 10/27/2011 | US20110263516 Vasodilator |
| 10/27/2011 | US20110263515 Capture agents and related compositions, methods and systems |
| 10/27/2011 | US20110263514 Delivery of agents using interfering nanoparticles |
| 10/27/2011 | US20110263513 Pharmaceutical Being Used For Treating Cancer and Fibrosis Disease and the Composition and Uses Thereof |
| 10/27/2011 | US20110263512 Conjugates for the treatment of mesothelioma |
| 10/27/2011 | US20110263511 Tight junction protein modulators and uses thereof |
| 10/27/2011 | US20110263510 Methods of Inhibiting Cell Death or Inflammation in a Mammal |
| 10/27/2011 | US20110263509 Preparation and use of high-purity hemoparatide (hpth-1-37) for the treatment of inflammatory scaling diseases of the skin |
| 10/27/2011 | US20110263508 Compositions and methods for including melanogenesis in a subject |
| 10/27/2011 | US20110263507 Peptide analogs that are potent and selective for human neurotensin receptor subtype 2 |
| 10/27/2011 | US20110263506 Peptides having an ace inhibiting effect |
| 10/27/2011 | US20110263505 Whey Protein Hydrolysate Containing Tryptophan Peptide Consisting of Alpha Lactalbumin and the Use Thereof |
| 10/27/2011 | US20110263504 Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| 10/27/2011 | US20110263503 Treatment of bleeding with low half-life fibrinogen |
| 10/27/2011 | US20110263502 Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| 10/27/2011 | US20110263501 Growth Hormone Conjugate with Increased Stability |
| 10/27/2011 | US20110263500 Curcumin Conjugates for Treating and Preventing Cancers |
| 10/27/2011 | US20110263499 Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants |
| 10/27/2011 | US20110263498 Method and composition for enhancement of male erectile function |
| 10/27/2011 | US20110263497 Apo a-i mimetic peptides and methods of treatment |
| 10/27/2011 | US20110263496 Exendins to lower cholesterol and triglycerides |
| 10/27/2011 | US20110263495 Methods and kits for treating disease by administering insulin-like growth factor binding protein-2 |
| 10/27/2011 | US20110263494 Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf-kappab acitivity and use thereof |
| 10/27/2011 | US20110263493 Treatment for diabetes in patients inappropriate for metformin therapy |
| 10/27/2011 | US20110263492 Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension of dispersion media |
| 10/27/2011 | US20110263491 Compositions and methods for the control, prevention and treatment of obesity and eating disorders |
| 10/27/2011 | US20110263490 Diagnostic Methods and Combination Therapies Involving MC4R |
| 10/27/2011 | US20110263489 Combination therapy to combat helminth resistance |
| 10/27/2011 | US20110263486 Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation |
| 10/27/2011 | US20110263485 Bifunctional Griffithsin Analogs |
| 10/27/2011 | US20110263484 Single chain fc type iii interferons and methods of using same |
| 10/27/2011 | US20110263483 Compositions and methods for treating pathologic angiogenesis and vascular permeability |
| 10/27/2011 | US20110263482 Complement inhibitors |
| 10/27/2011 | US20110263481 Pharmaceutical Composition of Lyophilized Formulation and Preparation Method of the Same |
| 10/27/2011 | US20110263480 Method for treating prostatitis utilizing modified pore-forming protein proaerolysin |
| 10/27/2011 | US20110263479 Peptides |
| 10/27/2011 | US20110263478 Sur1 inhibitors for therapy |
| 10/27/2011 | US20110263027 Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
| 10/27/2011 | US20110262545 Octreotide depot formulation with constantly high exposure levels |
| 10/27/2011 | US20110262541 Foam-formed collagen strand |
| 10/27/2011 | US20110262530 Sustained release of apo a-i mimetic peptides and methods of treatment |
| 10/27/2011 | US20110262527 Cationic lipids and methods of use |
| 10/27/2011 | US20110262525 Methods of treatment |
| 10/27/2011 | US20110262518 Treatment for cardiac injuries created by myocardial infarction |
| 10/27/2011 | US20110262508 Antimicrobial compositions, formulations and uses thereof |